Clinton spokeswoman defends drug plan after Pfizer comments
- Wall Street turns defensive on Trump's protectionist stance
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- Qualcomm (QCOM) Thrashed as Apple (AAPL) Lawsuit Threatens Licensing Business Model
- McDonald's (MCD) Tops Q4 EPS by 3c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
NEW YORK (Reuters) - U.S. Presidential candidate Hillary Clinton's spokeswoman said on Friday Clinton's plan to curb drug spending was not the blow to medical innovation that Pfizer Inc Chief Executive Ian Read described it as being on Thursday.
"Throughout this campaign, Hillary Clinton has called for expanding investments in innovation for healthcare, from a cure for Alzheimer's to building on Vice President Biden's Cancer Moonshot initiative," campaign spokeswoman Julie Wood said in an emailed statement.
"She's said clearly that our pharmaceutical and biotech industries are great sources of innovation and she wants to support their development of new treatments," she said.
Last week, Clinton unveiled a plan to create an oversight panel that would protect consumers from "unjustified" price hikes on life-saving drugs.
On Thursday, while speaking at an investor conference, Read said Clinton's plan would be "very negative for innovation." A Pfizer spokeswoman had no further comment on Friday.
Drugmakers have been criticized for raising drug prices in the United States, where citizens pay the most worldwide for medicines.
(Reporting by Caroline Humer and Ransdell Pierson)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi subsidiaries to pay $28.8 million over giving U.S. homeowners 'runaround': CFPB
- New York City reaches $75 million settlement over police summonses
- Nigerian musician Femi Kuti urges stars, fans to focus on Boko Haram victims
Create E-mail Alert Related CategoriesReuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!